Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lobato Cirley Maria de Oliveira, Codes Liana, Silva Giovanni Faria, Souza Aécio Flávio Meirelles, Coelho Henrique Sérgio Moraes, Pedroso Maria Lucia Alves, Parise Edison Roberto, Lima Leila Maria Soares Tojal de Barros, Borba Luiz Augusto, Evangelista Andreia Silva, Rezende Rosamar Eulira Fontes, Cheinquer Hugo, Kuniyoshi Aline Satie Oba, Aires Rodrigo Sebba, Quintela Eloiza Helena Dias, Mendes Liliana Sampaio Costa, Nascimento Fábio Carneiro Vosqui, Medeiros Filho José Eymard Moraes de, Ferraz Maria Lúcia Cardoso Gomes, Abdala Edson, Bittencourt Paulo Lisboa, Members of the Brazilian Real-Life Study about HCV treatment, Members of the Brazilian Real-Life Study about HCV treatment
Аннотация
MATERIALS AND METHODS: All Brazilian reference centers for HCV treatment were invited to take part in a web-based registry, prospectively conducted by the Brazilian Society of Hepatology, to assess outcomes of HCV treatment in Brazil with DAAs. Data to be collected included demographics, disease severity and comorbidities, genotype (GT), viral load, DAA regimens, treatment side effects and sustained virological response (SVR).
RESULTS: 3939 patients (60% males, mean age 58±10 years) throughout the country were evaluated. Most had advanced fibrosis or cirrhosis, GT1 and were treated with SOF/DCV or SOF/SIM. Overall SVR rates were higher than 95%. Subjects with decompensated cirrhosis, GT2 and GT3 have lower SVR rates of 85%, 90% and 91%, respectively. Cirrhosis and decompensated cirrhosis in GT1 and male sex and decompensated cirrhosis in GT3 were significantly associated with no SVR. Adverse events (AD) and serious AD occurred in 18% and 5% of those subjects, respectively, but less than 1% of patients required treatment discontinuation.
CONCLUSION: SOF-based DAA regimens are effective and safe in the heterogeneous highly admixed Brazilian population and could remain an option for HCV treatment at least in low-income countries.